Evrópusambandið - ítalska - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - belatacept - graft rejection; kidney transplantation - immunosoppressori - nulojix, in combination with corticosteroids and a mycophenolic acid (mpa), is indicated for prophylaxis of graft rejection in adult recipients of a renal transplant.

Evrópusambandið - ítalska - EMA (European Medicines Agency)

eli lilly nederland b.v. - dulaglutide - diabete mellito, tipo 2 - drugs used in diabetes, blood glucose lowering drugs, excl. insulins - trulicity is indicated for the treatment of patients 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes. per i risultati dello studio rispetto alle combinazioni di effetti sul controllo glicemico e di eventi cardiovascolari, e le popolazioni studiate, vedere sezioni 4. 4, 4. 5 e 5.

Evrópusambandið - ítalska - EMA (European Medicines Agency)

actavis group ptc ehf - reteplase - infarto miocardico - agenti antitrombotici - rapilysin is indicated for the thrombolytic treatment of suspected myocardial infarction with persistent st elevation or recent left bundle branch block within 12 hours after the onset of acute-myocardial-infarction (ami) symptoms.

Evrópusambandið - ítalska - EMA (European Medicines Agency)

pfizer europe ma eeig - lorlatinib - carcinoma, polmone non a piccole cellule - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.

Evrópusambandið - ítalska - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - ozanimod hydrochloride - multiple sclerosis, relapsing-remitting; colitis, ulcerative - immunosoppressori - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.

Ítalía - ítalska - AIFA (Agenzia Italiana del Farmaco)

eg s.p.a. - carvedilolo - carvedilolo

Evrópusambandið - ítalska - EMA (European Medicines Agency)

biogen netherlands b.v.  - fampridine - sclerosi multipla - altri farmaci sul sistema nervoso - fampyra è indicato per il miglioramento della deambulazione nei pazienti adulti con sclerosi multipla con disabilità motoria (expanded disability status scale 4-7).

Evrópusambandið - ítalska - EMA (European Medicines Agency)

ratiopharm gmbh - paclitaxel - neoplasie al seno - agenti antineoplastici - pazenir in monoterapia è indicato per il trattamento del tumore metastatico della mammella in pazienti adulti che hanno fallito il trattamento di prima linea per la malattia metastatica e per i quali standard, contenente antracicline terapia non è indicata. pazenir in combinazione con carboplatino è indicato per il trattamento di prima linea del polmone non a piccole cellule del cancro in pazienti adulti che non sono candidati per la chirurgia potenzialmente curativa e/o radioterapia.

Ítalía - ítalska - AIFA (Agenzia Italiana del Farmaco)

sigma-tau industrie farmaceutiche riunite spa - formoterolo - formoterolo

Evrópusambandið - ítalska - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - guanfacine cloridrato - disturbo da deficit di attenzione con iperattività - antiadrenergic agents, centrally acting, antihypertensives, - intuniv is indicated for the treatment of attention deficit hyperactivity disorder (adhd) in children and adolescents 6 17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective. intuniv deve essere utilizzato come parte di un completo trattamento dell'adhd programma, in genere, compresi psicologico, educativo e sociale, misure di.